CD22 and acute lymphoblastic leukemia: Still, certain subgroups of relapsed or refractory ALL patients benefit from several recently introduced therapies, including blinatumomab (bispecific anti CD3-CD19), inotuzumab ozogamycin (anti CD22), and CD19-targeting CAR-T cells.